Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merck & Co., Inc. (MRK): Should You Buy Into This Dow Dividend Dynamo?

The Dow Jones Industrial Average is taking a breather after its recent bullish charge. The blue-chip index is down 0.9% at midday, hurt by a cocktail of worrisome news on Mediterranean economies and a surprising pullback on rising oil prices. Of the 30 Dow components, 29 are in the red right now.

Amid the carnage, you’ll find pharma giant Merck & Co., Inc. (NYSE:MRK) dropping 2%. That’s the second-steepest fall on the Dow today. The macroeconomic worries were underscored by a couple of downgrades by analysts citing risks in Merck’s drug development pipeline.

Merck & Co., Inc. (NYSE:MRK)But pipeline risks are nothing new. Biotech and pharmaceuticals investors are used to dealing with the FDA wild card, and Merck’s drug-approval uncertainty is always priced into the stock.

Buy Merck today, and you’ll lock in a stellar 4.1% dividend yield. That’s richer than fellow Dow members Johnson & Johnson (NYSE:JNJ), at 3.3%, and Pfizer Inc. (NYSE:PFE), at 3.5%. In fact, Merck sports the fourth-richest yield on the Dow today, behind only the telecom cash machines and drastically undervalued semiconductor titan Intel Corporation (NASDAQ:INTC). I have personally found Intel’s yield irresistible, and Merck isn’t far behind.

And that’s not all. The quarterly payouts were frozen at $0.38 per share for seven years, starting in 2004. The dividend has been boosted twice in the last five quarters and now sits at $0.43 per share, per quarter.

MRK Dividend Chart

MRK Dividend data by YCharts.

This willingness to raise the payouts speaks volumes about Merck’s confidence in the current product pipeline.

Long story short, Merck’s dividend looks rich today but is likely to head even higher over the years. Investors with a yen for income-generation would do well to take a closer look at exploiting this opportunity.

The article Should You Buy Into This Dow Dividend Dynamo? originally appeared on and is written by Anders Bylund.

Fool contributor Anders Bylund owns shares of Intel, but he holds no other position in any company mentioned. Check out Anders’ bio and holdings or follow him on Twitter and Google+. The Motley Fool owns shares of Intel and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Intel and Johnson & Johnson. Motley Fool newsletter services have recommended buying calls on Johnson & Johnson. Motley Fool newsletter services have recommended writing puts on Intel.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!